Sztatin (Hungarian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Sztatin" in Hungarian language version.

refsWebsite

Global rank Hungarian rank

5researchgate.net

120^th place

344^th place

3nih.gov

4^th place

11^th place

2sciencedirect.com

149^th place

249^th place

2oup.com

485^th place

914^th place

2thelancet.com

2,393^rd place

8,307^th place

2nejm.org

2,374^th place

1,555^th place

1jwatch.org

low place

1bristol.ac.uk

9,207^th place

5,938^th place

1sagepub.com

731^st place

2,041^st place

1theguardian.com

12^th place

61^st place

1web.archive.org

1^st place

bristol.ac.uk

research-information.bristol.ac.uk

„13. Collins R, Reith C, Emberson J, et al.: Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388: 2532-2561. https://research-information.bristol.ac.uk/en/publications/interpretation-of-the-evidence-for-the-efficacy-and-safety-of-statin-therapy(8b30dafd-b26e-4de8-bdc1-8b7744b4f926)/export.html”.

jwatch.org

„6. US Preventive Services Task Force. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2016; 316:1997-2007. https://www.jwatch.org/na42851/2016/11/17/statins-primary-prevention-cardiovascular-disease-adults”.

nejm.org

„10. Yusuf S, Bosch J, Dagenais G, et al.; HOPE-3 Investigators. Cholesterol lowering in intermediate risk persons without cardiovascular disease. N Engl J Med 2016; 374: 2021–2031. https://www.nejm.org/doi/10.1056/NEJMoa1600176?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov”.
„11. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C reactive protein. N Engl J Med 2008; 359:2195–207. https://www.nejm.org/doi/10.1056/NEJMoa0807646?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov”.

nih.gov

ncbi.nlm.nih.gov

2. Durrington P. Dyslipidaemia. Lancet. 2003; 362:717-31. https://www.ncbi.nlm.nih.gov/pubmed/12957096
4. Catapano AL, Graham I, De Backer G, et al.: 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016; 37: 2999-3058. https://www.ncbi.nlm.nih.gov/pubmed/27567407
5. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018. pii: S0735-1097(18)39033-8. https://www.ncbi.nlm.nih.gov/pubmed/30423391

oup.com

academic.oup.com

3. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2016; 37: 2315-81. https://academic.oup.com/eurheartj/article/37/29/2315/1748952
„15. Stroes ES, Thompson PD, Corsini A, et al.: Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015; 36: 1012-1022. https://academic.oup.com/eurheartj/article/36/17/1012/2465952”.

researchgate.net

„7. National Clinical Guideline Centre (UK). London: National Institute for Health and Care Excellence (UK); Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. Clinical guideline [CG181] Published date: July 2014 Last updated: September 2016. https://www.researchgate.net/publication/279457963_Cardiovascular_risk_assessment_and_lipid_modification_NICE_guideline”.
„14. Mach F, Ray KK, Wiklund O, et al.: Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J 2018; 39: 2526-2539. https://www.researchgate.net/publication/324920096_Adverse_effects_of_statin_therapy_perception_vs_the_evidence_-_focus_on_glucose_homeostasis_cognitive_renal_and_hepatic_function_haemorrhagic_stroke_and_cataract”.
„17. Ravnskov U, Diamond DM, Hama R, et al. Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review. BMJ Open 2016;6:e010401. https://www.researchgate.net/publication/303719404_Lack_of_an_association_or_an_inverse_association_between_low-density-lipoprotein_cholesterol_and_mortality_in_the_elderly_A_systematic_review”.
„18. Horton, R. Offline: Lessons from the controversy over statins. Lancet 2016; DOI:10.1016/S0140-6736(16)31583-5. Editorial. https://www.researchgate.net/publication/308003070_Offline_Lessons_from_the_controversy_over_statins”.
„19. Schiele F, Kristensen SD. The anti-statin lobby strikes again: time to set the record straight. Eur Heart J. 2017 Dec 28. doi: 10.1093/eurheartj/ehx744. https://www.researchgate.net/publication/322213951_The_anti-statin_lobby_strikes_again_time_to_set_the_record_straight”.

sagepub.com

journals.sagepub.com

„16. Finegold JA, Manisty CH, Goldacre B, et al. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol. 2014; 21:464-74. https://journals.sagepub.com/doi/abs/10.1177/2047487314525531?journalCode=cprc”.

sciencedirect.com

„1. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. Lancet 2015; 385: 1397–405. https://www.sciencedirect.com/science/article/pii/S0140673614613684”.
„8. Giugliano RP, Pedersen TR, Park JG, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017; 390: 1962-1971. https://www.sciencedirect.com/science/article/pii/S0140673617322900”.

theguardian.com

„20. Boseley S (8 September 2016) "Statins prevent 80,000 heart attacks and strokes a year in UK, study finds". The Guardian. Retrieved 29 December 2017. https://www.theguardian.com/society/2016/sep/08/statins-prevent-80000-heart-attacks-and-strokes-a-year-in-uk-study-finds”.

thelancet.com

„9. Collins R, Armitage J, Parish S, et al.: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003; 361: 2005-2016. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)13636-7/fulltext?code=lancet-site”.
„12. Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019; 393: 407-415. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31942-1/fulltext”.

web.archive.org

„21. Husten L (24 July 2017). "Nissen Calls Statin Denialism A Deadly Internet-Driven Cult". CardioBrief. Archived from the original on 19 December 2017. Retrieved 19 December 2017. https://web.archive.org/web/20171219010101/http://www.cardiobrief.org/2017/07/24/nissen-calls-statin-denialism-a-deadly-internet-driven-cult/”.